Genmab acquires exclusive protein development rights  

2006.02.22
Danish-American biotech firm Genmab has acquired exclusive worldwide rights to develop therapeutics based on a number of angiogenesis targets identified by Bionomics

The Danish-American biotech firm Genmab has acquired exclusive worldwide rights to develop therapeutics based on a number of angiogenesis targets identified by Bionomics, an Australian company specialising in discovery and development of therapeutics for the treatment of cancer and CNS diseases. Under the agreement, Genmab gets the worldwide rights to eight proteins.

Lisa N. Drakeman, chief executive officer of Genmab comments: "We are pleased to exclusively license these targets from Bionomics, with which we have had an excellent working relationship since early 2002". She also says that the targets further enrich and strengthen Genmab's growing pre-clinical pipeline. Bionomics will receive an up-front fee and additional milestone payments. The news was reported by BiotechDenmark.

Genmab A/S creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. The company has a portfolio of products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions. Genmab currently has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche, Amgen and Serono. Genmab has operations in Copenhagen, Denmark, Utrecht, the Netherlands, and Princeton, New Jersey in the US.

Link> Genmab 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×